Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Inflammatory Disease Clear all
Completed Phase 4 Interventional Results available

Steroids After Laser Trabeculoplasty for Glaucoma

NCT00981435
View directory record Official record
Conditions
Glaucoma
Interventions
Prednisolone 1%, Ketorolac, Artificial Tears
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 10, 2026, 9:19 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

NCT06585670
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
Calm Health - smartphone application
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 10, 2026, 9:19 PM EDT
Not listed Phase 2 Interventional Results available

Tofacitinib for Inflammatory Eye Disease

NCT03580343
View directory record Official record
Conditions
Uveitis, Scleritis
Interventions
tofacitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Olopatadine on Allergic Tear Mediators

NCT00609128
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Phase 2 Interventional

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

NCT00001311
View directory record Official record
Conditions
Cataracts
Interventions
heparin-surface modified intraocular lens
Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:19 PM EDT
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
View directory record Official record
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:19 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 9:19 PM EDT
Completed No phase listed Observational

Differences in Genes and Proteins in Active and Controlled Uveitis

NCT00357266
View directory record Official record
Conditions
Ocular Inflammatory Disease, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jun 10, 2026, 9:19 PM EDT
Terminated Phase 4 Interventional

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

NCT00597181
View directory record Official record
Conditions
Glaucoma
Interventions
Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528
View directory record Official record
Conditions
Sjogren's Disease
Interventions
Administration of Lotemax
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jun 10, 2026, 9:19 PM EDT
Completed No phase listed Observational

Analysis of Eye Tissue

NCT00001224
View directory record Official record
Conditions
Eye Disease, Inflammation, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:19 PM EDT
Not listed Phase 4 Interventional

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

NCT04592081
View directory record Official record
Conditions
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Kerry Assil, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 9:19 PM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jun 10, 2026, 9:19 PM EDT
Terminated Early Phase 1 Interventional

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596
View directory record Official record
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease

NCT01787825
View directory record Official record
Conditions
Intestinal Disease, Inflammatory Bowel Disease, Crohn Disease, Ulcer, Celiac Disease
Interventions
PillCam SB2 capsule, CapsoCam SV-1
Device
Lead sponsor
Capso Vision, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Miami, Florida • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jun 10, 2026, 9:19 PM EDT
Completed No phase listed Observational

Study of Eye Tissue for Sarcoidosis

NCT00001278
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:19 PM EDT
Active, not recruiting Not applicable Interventional

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT05715463
View directory record Official record
Conditions
Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions
Resource sheets, Community Resource Specialist, Nurse Navigator
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 9:19 PM EDT
Active, not recruiting Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 9:19 PM EDT
Completed Phase 1 Interventional

Vitamin E to Treat Uveitis-Associated Macular Edema

NCT00021645
View directory record Official record
Conditions
Cystoid Macular Edema, Uveitis
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:19 PM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

NCT00006188
View directory record Official record
Conditions
Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:19 PM EDT
Recruiting No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jun 10, 2026, 9:19 PM EDT